Exagen initiates study to predict rheumatoid arthritis drug response (radr) in patients with ra

San diego, aug. 04, 2022 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis using the avise® radr platform. the goal of the treatment stratification using gene expression profiling in rheumatoid arthritis (tiger) study is to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue accurately predict response to antirheumatic medications. the tiger study is the next step in exagen's process of bringing avise® radr to market.
XGN Ratings Summary
XGN Quant Ranking